Pharmacokinetics and pharmacodynamics of alirocumab in patients with autosomal dominant hypercholesterolemia associated with PCSK9 gain-of-function or ApoB loss-of-function mutations

被引:0
|
作者
Hopkins, P. N. [1 ]
Krempf, M. [2 ]
Bruckert, E. [3 ]
Luc, G. [4 ]
Donahue, S. [5 ]
Yang, F. [5 ]
Zhang, Y. [5 ]
Dicioccio, A. T. [5 ]
机构
[1] Univ Utah, Sch Med, Salt Lake City, UT USA
[2] CHU Nantes, Hop Nord Laennec, St Herblain, France
[3] Hosp Pitie Salpetriere, Paris, France
[4] Univ Lille 2, Lille, France
[5] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
352
引用
收藏
页码:49 / 49
页数:1
相关论文
共 50 条
  • [1] Pharmacodynamics of Alirocumab in Patients With Autosomal Dominant Hypercholesterolemia Associated With PCSK9 Gain-Of-Function or ApoB Loss-Of-Function Mutations: An Open-Label Extension Study
    Krempf, Michel
    Hopkins, Paul N.
    Bruckert, Eric
    Luc, Gerald
    Lee, Shane
    Donahue, Stephen
    CIRCULATION, 2018, 138
  • [2] Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody
    Hopkins, Paul N.
    Defesche, Joep
    Fouchier, Sigrid W.
    Bruckert, Eric
    Luc, Gerald
    Cariou, Bertrand
    Sjouke, Barbara
    Leren, Trond P.
    Harada-Shiba, Mariko
    Mabuchi, Hiroshi
    Rabes, Jean-Pierre
    Carrie, Alain
    van Heyningen, Charles
    Carreau, Valerie
    Farnier, Michel
    Teoh, Yee P.
    Bourbon, Mafalda
    Kawashiri, Masa-aki
    Nohara, Atsushi
    Soran, Handrean
    Marais, A. David
    Tada, Hayato
    Abifadel, Marianne
    Boileau, Catherine
    Chanu, Bernard
    Katsuda, Shoji
    Kishimoto, Ichiro
    Lambert, Gilles
    Makino, Hisashi
    Miyamoto, Yoshihiro
    Pichelin, Matthieu
    Yagi, Kunimasa
    Yamagishi, Masakazu
    Zair, Yassine
    Mellis, Scott
    Yancopoulos, George D.
    Stahl, Neil
    Mendoza, Johanna
    Du, Yunling
    Hamon, Sara
    Krempf, Michel
    Swergold, Gary D.
    CIRCULATION-CARDIOVASCULAR GENETICS, 2015, 8 (06) : 823 - 831
  • [3] Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia
    Abifadel, Marianne
    Guerin, Maryse
    Benjannet, Suzanne
    Rabes, Jean-Pierre
    Le Goff, Wilfried
    Julia, Zelie
    Hamelin, Josee
    Carreau, Valerie
    Varret, Mathilde
    Bruckert, Eric
    Tosolini, Laurent
    Meilhac, Olivier
    Couvert, Philippe
    Bonnefont-Rousselot, Dominique
    Chapman, John
    Carrie, Alain
    Michel, Jean-Baptiste
    Prat, Annik
    Seidah, Nabil G.
    Boileau, Catherine
    ATHEROSCLEROSIS, 2012, 223 (02) : 394 - 400
  • [4] Efficacy and Safety of Alirocumab in Patients With Autosomal Dominant Hypercholesterolemia Associated With Proprotein Convertase Subtilisin/Kexin Type 9 Gain-of-Function or Apolipoprotein B Loss-of-Function Mutations
    Krempf, Michel
    Hopkins, Paul N.
    Bruckert, Eric
    Lee, Shane
    Donahue, Stephen
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 125 (06): : 880 - 886
  • [5] LIPOPROTEIN(A) IN FAMILIAL HYPERCHOLESTEROLEMIA WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
    Tada, Hayato
    Kawashiri, Masa-Aki
    Nohara, Atsushi
    Inazu, Akihiro
    Mabuchi, Hiroshi
    Yamagishi, Masakazu
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 1896 - 1896
  • [6] SCREENING FOR PCSK9 MUTATIONS IN SPANISH PATIENTS WITH AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA UNRELATED TO LDLR OR APOB
    Garcia-Otin, L.
    Strunk, M.
    Pueyo, M.
    Solanas, M.
    Fiddyment, S.
    Aceves, M.
    Tejedor, D.
    Pocovi, M.
    Civeira, F.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [7] Loss-of-Function PCSK9 Mutations Are Not Associated With Alzheimer Disease
    Paquette, Martine
    Saavedra, Yascara Grisel Luna
    Poirier, Judes
    Theroux, Louise
    Dea, Doris
    Baass, Alexis
    Dufour, Robert
    JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY, 2018, 31 (02) : 90 - 96
  • [8] Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
    Marianne Abifadel
    Mathilde Varret
    Jean-Pierre Rabès
    Delphine Allard
    Khadija Ouguerram
    Martine Devillers
    Corinne Cruaud
    Suzanne Benjannet
    Louise Wickham
    Danièle Erlich
    Aurélie Derré
    Ludovic Villéger
    Michel Farnier
    Isabel Beucler
    Eric Bruckert
    Jean Chambaz
    Bernard Chanu
    Jean-Michel Lecerf
    Gerald Luc
    Philippe Moulin
    Jean Weissenbach
    Annick Prat
    Michel Krempf
    Claudine Junien
    Nabil G Seidah
    Catherine Boileau
    Nature Genetics, 2003, 34 : 154 - 156
  • [9] Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
    Abifadel, M
    Varret, M
    Rabès, JP
    Allard, D
    Ouguerram, K
    Devillers, M
    Cruaud, C
    Benjannet, S
    Wickham, L
    Erlich, D
    Derré, A
    Villéger, L
    Farnier, M
    Beucler, I
    Bruckert, E
    Chambaz, J
    Chanu, B
    Lecerf, JM
    Luc, G
    Moulin, P
    Weissenbach, J
    Prat, A
    Krempf, M
    Junien, C
    Seidah, NG
    Boileau, C
    NATURE GENETICS, 2003, 34 (02) : 154 - 156
  • [10] Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtitisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations
    Hopkins, Paul N.
    Krempf, Michel
    Bruckert, Eric
    Donahue, Stephen
    Yang, Feng
    Zhang, Yi
    DiCioccio, A. Thomas
    JOURNAL OF CLINICAL LIPIDOLOGY, 2019, 13 (06) : 970 - 978